PD Frontline (Part of RAPSODI GD) Remote Assessment of People With Parkinson's

Recruiting

• Conditions: Parkinson Disease

• Registration Number: NCT06151002
• Lead Sponsor: University College London Hospitals

Brief Summary

PD Frontline (part of RAPSODI GD) is an online study observational study with the goal of bringing People with Parkinson's to the frontline of research by getting them trial ready. To do this, participants are offered genetic sequencing for the GBA and LRRK2 gene with an at-home saliva collection kit.

Detailed Description

PD Frontline is an online one-time questionnaire based study with the purpose of identifying potential candidates for gene targeted trials and observational studies.

Once the questionnaire is completed, the participant is sent a saliva collection kit in the post to provide a sample for genetic testing. The genes tested for are GBA1, the most common risk factor gene for Parkinson's, and LRRK2.

Once tested, the participant is informed of their results and kept up-to-date with any studies or trials for which they may be eligible.

Study Timeline

• Study Start: 2020-02-15
• Study First Submitted: 2023-10-11
• Status Verified: 2023-11
• Study First Submitted QC: 2023-11-28
• Last Update Submitted: 2023-11-28
• Study First Posted: 2023-11-30
• Last Update Posted: 2023-11-30
• Primary Completion: 2025-02-14
• Study Completion: 2040-08-20

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 4800

Inclusion Criteria

• Formal diagnosis of Parkinson Disease

Exclusion Criteria

• Confirmation that the individual carries a GBA variant (GBA positive). These individuals will be referred to sister-study, RAPSODI.
• History of Parkinsonism (progressive supranuclear palsy, multiple system atrophy, traumatic, manganese toxicity, postencephalitic, vascular PD; drug induced PD; corticobasal degeneration)
• Individuals with another neurological disorder including: dementia, movement disorders, and motor neurone disease.
• Individuals on drugs known to be associated with parkinsonism, including neuroleptic agents (Amisulpride, Chlorpromazine Hydrochloride, Flupenthixol, Fluphenazine Hydrochloride, Haloperidol, Methotrimeprazine, Levomepromazine, Olanzapine, Oxypertine, Pericyazine, Perphenazine, Pimozide, Pipotiazine, Prochlorperazine, Promazine Hydrochloride, Reserpine, Risperidone, Sulpiride, Thioridazine, Trifluoperazine, Zuclopenthixol acetate, Zotepine), plus Bupropion, , Lithium, Methyldopa, Metoclopramide and Sodium Valproate).

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Genotype of participants	20 years	The primary outcome of the study is to genotype the GBA1 gene, obtained with Oxford Nanopore long read sequencing.

Trial Locations

Locations (1)

University College London (UCL); 🇬🇧 London, United Kingdom